Skip to main content
SpringerLink
Log in

SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Purpose

Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly.

Methods

Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays. A total of 186 patients (116 women, age range 26–88 years) were evaluated.

Results

No association of SOCS2 genotypes was observed with none of the following clinical and laboratorial characteristics: age, sex, body mass index, comorbidities, basal GH, oral glucose tolerance test GH nadir, IGF-I, ULNR-IGF-I.

Conclusion

Despite of the key role of SOCS2 in the regulation of GH receptor signaling, we did not find any significant association between SOCS2 polymorphisms and acromegaly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lugo G, Pena L, Cordido F (2012) Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol 2012:540398

    Article  PubMed  PubMed Central  Google Scholar 

  2. Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M, Bakker B (2013) Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med 6:31–38

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537–3542

    Article  CAS  PubMed  Google Scholar 

  4. Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166–170

    Article  CAS  Google Scholar 

  5. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89:495–500

    Article  CAS  PubMed  Google Scholar 

  6. Mercado M et al (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62:293–299

    CAS  PubMed  Google Scholar 

  7. Alexopoulou O et al (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324–1330

    Article  CAS  PubMed  Google Scholar 

  8. Machado EO et al (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18:389–393

    Article  CAS  PubMed  Google Scholar 

  9. Elias PC et al (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42:50–55

    Article  CAS  PubMed  Google Scholar 

  10. Brzana JA et al (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15:562–570

    Article  CAS  PubMed  Google Scholar 

  11. Hartman ML et al (1990) Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 70:1375–1384

    Article  CAS  PubMed  Google Scholar 

  12. Veldhuis JD (1996) Gender differences in secretory activity of the human somatotropic (growth hormone) axis. Eur J Endocrinol 134:287–295

    Article  CAS  PubMed  Google Scholar 

  13. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM (2001) The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 86:259–266

    Article  CAS  PubMed  Google Scholar 

  14. Matta M et al (2011) Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment. Eur J Endocrinol 164:885–889

    Article  CAS  PubMed  Google Scholar 

  15. Bianchi A et al (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015–2022

    Article  CAS  PubMed  Google Scholar 

  16. Cinar N et al (2015) The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly. Pituitary 18:116–125

    Article  CAS  PubMed  Google Scholar 

  17. Metcalf D et al (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069–1073

    Article  CAS  PubMed  Google Scholar 

  18. Paternoster L et al (2011) Adult height variants affect birth length and growth rate in children. Hum Mol Genet 20:4069–4075

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gudbjartsson DF et al (2008) Many sequence variants affecting diversity of adult human height. Nat Genet 40:609–615

    Article  CAS  PubMed  Google Scholar 

  20. Braz AF et al (2014) Genetic Predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and turner syndrome: the influence of a SOCS2 polymorphism. J Clin Endocrinol Metab 99:E1808–E1813

    Article  CAS  PubMed  Google Scholar 

  21. Rico-Bautista E, Flores-Morales A, Fernández-Pérez L (2006) Suppressor of cytokine signaling (SOCS)2, a protein with multiple functions. Cytokine Growth Factor Rev 17:431–439

    Article  CAS  PubMed  Google Scholar 

  22. Trengove MC, Ward AC (2013) SOCS proteins in development and disease. Am J Clin Exp Immunol 2:1–29

    PubMed  PubMed Central  Google Scholar 

  23. Jallad RS, Trarbach EB, Duarte FH, Jorge AA, Bronstein MD (2015) Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly. Pituitary 18:666–673

    Article  CAS  PubMed  Google Scholar 

  24. Bogazzi F et al (2009) Changes in the expression of suppressor of cytokine signalling (SOCS)2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps. Clin Endocrinol (Oxf) 70:898–906

    Article  CAS  Google Scholar 

  25. Buslei R et al (2006) Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas. Acta Neuropathol 111:264–271

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thanks to Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) for the financial support.

Funding

This study was funded in part by Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP (Grant Number 2010/11718-1).

Author information

Authors and Affiliations

  1. Laboratory of Cellular and Molecular Endocrinology - LIM25, Clinical Hospital of the University of São Paulo Medical School, Av Dr Arnaldo, 455, 4 andar, sala 4345, São Paulo, SP, CEP: 01246-903, Brazil

    Ericka B. Trarbach & Alexander A. Jorge

  2. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinical Hospital of the University of São Paulo Medical School, Av Dr Eneas de Carvalho Aguiar, 155, PAMB, 8 andar, São Paulo, SP, CEP: 05403-010, Brazil

    Felipe H. Duarte, Marcello D. Bronstein & Raquel S. Jallad

Authors
  1. Ericka B. Trarbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander A. Jorge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe H. Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcello D. Bronstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raquel S. Jallad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ericka B. Trarbach.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trarbach, E.B., Jorge, A.A., Duarte, F.H. et al. SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients. Pituitary 20, 319–324 (2017). https://doi.org/10.1007/s11102-016-0779-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-016-0779-1

Keywords

Search

Navigation